"Red light therapy" covers two different things, and only one of them has anything to do with fat. On one side are 635 nm low-level laser systems, Erchonia and Zerona. They hold real FDA clearances for reducing body circumference. On the other side are the red-light panels and masks sold for skin and recovery. Those are a different product with a different purpose.
The laser clearances are real, and they are circumference clearances. The FDA created the category for them on 24 August 2010, through a De Novo request, DEN090008, granted to Erchonia. The device class it created is called "Fat Reducing Low Level Laser". Every Erchonia and Zerona clearance since then reads some version of "reduction of circumference". The part of the body named is the arms, hips, waist, thighs or upper abdomen, depending on the model.
Circumference is a tape measure around a body part. It is not the thickness of the fat layer, it is not fat volume, and it is not weight. These are four different measurements. The two devices on this page are cleared and measured on different ones. CoolSculpting's clearance is for cold-assisted lipolysis of named fat bulges. The number quoted for it, 20 to 25 per cent, is a percentage of the thickness of the fat layer at one measuring point.
A red-light panel bought online for skin or recovery is not cleared for fat or circumference, unless that exact model holds one of those clearances. Some consumer devices do hold one: the Zerona Z6 OTC (K143007), the Zerona Z-Bed (K220519) and the Contour Light CL-100 (K202955). Most panels sold as wellness products do not. The clearance belongs to the model, not to the colour of the light. So the only way to know is to check the model.
Zerona is the best-known laser brand. The consumer panels sold for skin, sleep and muscle recovery are a separate market.
It was authorised through a De Novo request, DEN090002, decided 24 August 2010. That request created the FDA device category for cryolipolysis.
No clearance in this class describes destroying fat cells. One low-level laser clearance in the same category is written for the temporary reduction of waist circumference. It describes the mechanism as disrupting fat cells so they release fat and lipids, rather than killing them (BTL-9000, K134040, 2014). Nothing is heated and nothing is felt.
Scavenger cells clear the dead cells over the following weeks. Pivotal settings in the FDA files are minus 10 degrees Celsius for 60 minutes under the chin, and minus 11 degrees for 35 minutes on the arm.
Upper arms (K120257, 2012). Hips, waist and thighs, alongside planned liposuction (K123237, 2013). Hips, waist and thighs without the liposuction wording, over the counter (K143007, 2015). Hips, waist, thighs and upper abdomen at a body mass index between 25 and 40 (K150446, 2015). Body circumference at a body mass index up to 40 (Erchonia Emerald, K192544, 2020). A 510(k) clearance means the FDA agreed the device is much the same as one already on the market. It is not a finding that the device works.
CoolSculpting Elite, K212707, cleared 5 November 2021. The submental and submandibular areas, under the chin and jaw, are cleared separately, up to a body mass index of 46.2.
Circumference moves with posture, breath, tape tension, time of day, meals and fluid. No published study reports how much a body-contouring circumference measurement varies on its own. So there is no published noise floor to compare a result against.
Blinded photo picking is the main endpoint in most CoolSculpting clearances. It is a spot-the-difference test, not a measurement of fat. The FDA's own pooled review inside K160259 put mean ultrasound fat-layer reduction at 20.6 per cent, across a range of 10.3 to 25.5 per cent. An independent randomised split-body trial found about 14 per cent (Dahmann 2023).
The largest sham-controlled trial reported a combined 3.51 inches across waist, hips and both thighs. It also reported that 0.31 of those inches had come back two weeks after the course stopped.
No adverse events were reported in the sham-controlled laser trials.
Delayed pain arriving a few days after treatment is common. One review of 554 procedures found it lasted 3 to 11 days and cleared on its own. Numbness past 12 weeks happened in 4 of 30 patients in the FDA-reviewed arm study.
The effect was measured at the end of the course. One trial found part of it had come back within two weeks of stopping.
In the largest real-world review, covering 3,262 patients, the median was 4 cycles and 1 session per patient.
CoolSculpting, Zerona and four other unrelated products were pooled into one line in the American Society of Plastic Surgeons 2023 fee table, at $1,157. That is a category average across six different treatments, including an injectable. It is not a price for any one of them, and the society stopped publishing the line after 2023.
It is priced per cycle rather than per session, which is why patient-reported totals scatter so widely.
Three trials found circumference reductions, and one found none: They should be read together.
Jackson and colleagues in 2009 ran the pivotal Zerona study. It was double-blind, randomised and sham-controlled, with 67 people at a body mass index of 25 to 30, treated three times a week for two weeks. The treated group lost a combined 3.51 inches across waist, hips and both thighs. The sham group lost 0.684 inches. The same paper reports that two weeks after the course finished, the treated group had regained 0.31 inches.
Nestor and colleagues in 2012 treated upper arms in 40 people, half of them sham-treated. The result was a combined 3.7 cm against 0.2 cm. That study was funded by a research grant from Erchonia Corporation. The lead author has received speaking fees from Erchonia and from Zeltiq, the maker of CoolSculpting. Roche and colleagues in 2017 treated 53 people at a body mass index of 30 to 40. They reported a combined 10.52 cm against 1.80 cm. The paper says outright that the device was cleared by the FDA on the strength of it. One of its authors is affiliated with Erchonia Corporation.
Against those sits Elm and colleagues in 2011. It was a split-body test of the Erchonia laser used in the Zerona system. It was small, at five people, and it is the clearest independent test in the set. It found no meaningful reduction in circumference at 7 days or 1 month. It found no meaningful reduction in fat-layer thickness on ultrasound. And the blinded photo identification rate was 51.1 per cent, which is chance. Three of the five recorded themselves as dissatisfied, and all five said the effect was less than they expected. The authors concluded that more evidence was needed before low-level laser therapy could be recommended.
A centimetre off a waist and a millimetre off a fat layer are not the same finding. Neither one converts into the other. Circumference includes skin, fat, muscle, gut contents and fluid, and it changes across a day. Fat-layer thickness measures one tissue at one point, through the skin, on one axis.
This matters because the two products are cleared on different endpoints, so their headline numbers are not rivals: A device cleared to reduce circumference has never been asked to show it removed fat. A device cleared for lipolysis has never been asked to show a tape measure moved. Anyone putting "3.5 inches" next to "25 per cent" is comparing two different things that happen to both be numbers.
The FDA says this in plain words on its own page about non-invasive body contouring, last updated 15 October 2025: "Non-invasive body contouring does not treat obesity or improve your health. It will not result in weight loss or contribute to the health benefits associated with weight loss." CoolSculpting's maker says the same in its own safety information. The procedure "is not a treatment for weight loss".
That framing comes from the regulator and the manufacturer. No professional society has published a position statement saying it. The body mass index limits written into the clearances are ceilings on who may be treated. They are not targets the treatment is meant to move.
If you are considering the laser, ask which model the clinic owns and what its clearance says: The clearances in this class differ by body area and by body mass index range. Some are for use alongside liposuction rather than instead of it. The clinic should be able to name the device and the number.
If you are considering CoolSculpting, three blood disorders rule it out completely: They are cryoglobulinemia, cold agglutinin disease and paroxysmal cold hemoglobinuria. In all three, blood reacts badly to cold, which is why a cold treatment is off the table. Tell your provider in advance about cold urticaria, Raynaud's disease, pernio or chilblains. Mention any bleeding disorder or blood thinner, and any reduced feeling or poor circulation in the area. Mention any hernia in or next to the treatment site too. Hernia appears on the FDA's own risk list for this class, and on the maker's precaution list.
Fever or chills after treatment
Redness around a treated area that is visibly spreading hour by hour
Pus or discharge from treated skin
These are signs of a spreading infection and need urgent care the same day.
A firm, well-defined lump appears in a CoolSculpting-treated area two to six months later, above all if it matches the shape of the applicator
Numbness in a treated area is still there after about three months
Pain in a treated area is rising rather than settling after the first two weeks
The skin over a treated area darkens a lot over the following weeks
An area starts to look hollow or dented next to the other side
Blistering, crusting or an open area appears on treated skin
The firm lump on that list is paradoxical adipose hyperplasia. It is a rare complication of cryolipolysis in which the treated area gets bigger instead of smaller. It does not clear up on its own, and correction is surgical. Published incidence estimates disagree by about a hundredfold, largely because some count cycles and some count patients.
None of that applies to red light therapy. It is not a risk there, because there is no cooling and no cell death.